Supplementary Tables 1 - 3 from Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
posted on 2023-03-31, 17:15authored byElizabeth Fox, Brigitte C. Widemann, Meredith K. Chuk, Leigh Marcus, Alberta Aikin, Patricia O. Whitcomb, Maria J. Merino, Maya Lodish, Eva Dombi, Seth M. Steinberg, Samuel A. Wells, Frank M. Balis
PDF file - 118K, Supplemental Data Table 1: Additional Eligibility Criteria. Supplemental Table 2: Drugs that are generally accepted as having a risk of causing Torsades de Pointes and were restricted during enrollment on this clinical trial. Supplemental Table 3: Schedule of Required Evaluations.